NEW! Investment Companies Centre
Virgin Credit Card:
£0.91m
0.000p ()
2.50p
Date: Tuesday 23 Sep 2008
ReGen Therapeutics narrowed first half pre-tax losses to £1.12m compared to £1.6m last time. The roll out of the group’s nutraceutical product Colostrinin is continuing in line with expectations.
| Small caps round-up: Beximco, Medicsight, Mobile... | 12-May-2008 | ShareCast |
| Mobile Streams hit by goodwill charge | 26-Mar-2008 | ShareCast |
| London close: Footsie hits 5-month low | 15-Jan-2008 | ShareCast |
| London afternoon: Footsie drops through 6,100 | 15-Jan-2008 | ShareCast |
| Mobile Streams expects lower profit | 15-Jan-2008 | ShareCast |
| Change of Adviser - Amendment | 11-Nov-2008 | 17:57 | BW |
| HBO Partnership | 13-Oct-2008 | 07:00 | RNS |
| Change of Adviser Name | 07-Oct-2008 | 17:51 | RNS |
| Holding(s) in Company | 26-Sep-2008 | 08:00 | RNS |
| Interim Results | 23-Sep-2008 | 07:00 | RNS |
| Parry takes post at YouGov | 16-Jan-2007 | Guardian |
| Houlton seals first stake | 14-Jan-2007 | Scotland on Sunday |
| Market report: Friday latest | 04-Apr-2008 | Daily Mail |
| Market report: Tuesday latest | 07-Aug-2007 | Daily Mail |
| Lonmin sales scare keeps lid on FTSE 100 gains | 17-Jul-2007 | The Independent |
| The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
| Aim market: Quantity not quality brings expectat... | 18-Sep-2006 | Telegraph |
No recent information was found.
| Market report: Tuesday close | 07-Aug-2007 | This Is Money |
| Fallout from Monstermob; is it justified for Mob... | 16-Jan-2006 | Proactive Investors |
| Currency | UK Pounds |
| Share Price | 2.50p |
| Closing Price Change | 0.000p |
| 52 Week High | 19.50 |
| 52 Week Low | 1.75 |
| Volume | 479,219 |
| Shares Issued | 36.27m |
| Market Cap | £0.91m |
| Beta | 0.08 |
| RiskGrade | 300 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 10:50 | 479,219 @ 1.00p |
| CEO | Simon David Buckingham |
| Finance Director | James Colquhoun |